These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37293849)

  • 1. European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.
    Otero-Romero S; Lebrun-Frénay C; Reyes S; Amato MP; Campins M; Farez M; Filippi M; Hacohen Y; Hemmer B; Juuti R; Magyari M; Oreja-Guevara C; Siva A; Vukusic S; Tintoré M
    Eur J Neurol; 2023 Aug; 30(8):2144-2176. PubMed ID: 37293849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.
    Otero-Romero S; Lebrun-Frénay C; Reyes S; Amato MP; Campins M; Farez M; Filippi M; Hacohen Y; Hemmer B; Juuti R; Magyari M; Oreja-Guevara C; Siva A; Vukusic S; Tintoré M
    Mult Scler; 2023 Jul; 29(8):904-925. PubMed ID: 37293841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.
    Montalban X; Gold R; Thompson AJ; Otero-Romero S; Amato MP; Chandraratna D; Clanet M; Comi G; Derfuss T; Fazekas F; Hartung HP; Havrdova E; Hemmer B; Kappos L; Liblau R; Lubetzki C; Marcus E; Miller DH; Olsson T; Pilling S; Selmaj K; Siva A; Sorensen PS; Sormani MP; Thalheim C; Wiendl H; Zipp F
    Eur J Neurol; 2018 Feb; 25(2):215-237. PubMed ID: 29352526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology.
    Brieva L; Estruch BC; Merino JAG; Meca-Lallana V; Río J; Rodríguez-Antigüedad A; Agüera E; Ara JR; Luque AA; Garcia CA; Blanco Y; Castillo-Triviño T; Costa-Frossard L; González Platas M; Pascual LL; Llaneza-González M; Ginés MLM; Matías-Guiu J; Meca-Lallana JE; Bilbao MM; Sempere AP; Romero-Pinel L; Saiz A; Moral E
    Mult Scler Relat Disord; 2022 Jul; 63():103805. PubMed ID: 35512501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Rae-Grant A; Day GS; Marrie RA; Rabinstein A; Cree BAC; Gronseth GS; Haboubi M; Halper J; Hosey JP; Jones DE; Lisak R; Pelletier D; Potrebic S; Sitcov C; Sommers R; Stachowiak J; Getchius TSD; Merillat SA; Pringsheim T
    Neurology; 2018 Apr; 90(17):777-788. PubMed ID: 29686116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society.
    Lebrun C; Vukusic S; ;
    Rev Neurol (Paris); 2019 Jun; 175(6):341-357. PubMed ID: 31036391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
    Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations.
    Brownlee WJ; Wolf C; Hartung HP; Dingermann T; Anshasi N; Clark RA; Trojano M; Selmaj K; Uitdehaag BM; Tur C; Wuerfel J; Dallmann G; Witte J; Sintzel M; Bobrovnikova O; Cohen JA
    Mult Scler; 2022 Dec; 28(14):2177-2189. PubMed ID: 36000489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine.
    Etemadifar M; Sedaghat N; Nouri H; Lotfi N; Chitsaz A; Khorvash R; Zolfaghari H; Ghasemi Movaghar A; Pourabbas M; Salari M
    Mult Scler Relat Disord; 2022 Jan; 57():103417. PubMed ID: 34875487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.
    Montalban X; Gold R; Thompson AJ; Otero-Romero S; Amato MP; Chandraratna D; Clanet M; Comi G; Derfuss T; Fazekas F; Hartung HP; Havrdova E; Hemmer B; Kappos L; Liblau R; Lubetzki C; Marcus E; Miller DH; Olsson T; Pilling S; Selmaj K; Siva A; Sorensen PS; Sormani MP; Thalheim C; Wiendl H; Zipp F
    Mult Scler; 2018 Feb; 24(2):96-120. PubMed ID: 29353550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Farez MF; Correale J; Armstrong MJ; Rae-Grant A; Gloss D; Donley D; Holler-Managan Y; Kachuck NJ; Jeffery D; Beilman M; Gronseth G; Michelson D; Lee E; Cox J; Getchius T; Sejvar J; Narayanaswami P
    Neurology; 2019 Sep; 93(13):584-594. PubMed ID: 31462584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity-Does it matter?
    Tütüncü M; Demir S; Arslan G; Dinç Ö; Şen S; Gündüz T; Uzunköprü C; Gümüş H; Tütüncü M; Akçin R; Özakbaş S; Köseoğlu M; Bünül SD; Gezen O; Tezer DÇ; Baba C; Özen PA; Koç R; Elverdi T; Uygunoğlu U; Kürtüncü M; Beckmann Y; Doğan İG; Turan ÖF; Boz C; Terzi M; Tuncer A; Saip S; Karabudak R; Kocazeybek B; Efendi H; Bilge U; Siva A
    Mult Scler Relat Disord; 2023 Jul; 75():104761. PubMed ID: 37247488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
    Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
    Front Immunol; 2021; 12():796482. PubMed ID: 35111162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis.
    Mariottini A; Bertozzi A; Marchi L; Di Cristinzi M; Mechi C; Barilaro A; Massacesi L; Repice AM
    J Neurol; 2022 Jun; 269(6):2840-2847. PubMed ID: 35239006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementing education: Personal communication with a healthcare professional is a critical step to address vaccine hesitancy for people with multiple sclerosis.
    Panisset MG; Kilpatrick T; Cofré Lizama LE; Galea MP
    Mult Scler Relat Disord; 2022 Jul; 63():103933. PubMed ID: 35671672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expert opinion on the use of contraception in people with multiple sclerosis.
    Hillert J; Bove R; Haddad LB; Hellwig K; Houtchens M; Magyari M; Merki-Feld GS; Montgomery S; Nappi RE; Stenager E; Thompson H; Tulek Z; Verdun Di Cantogno E; Simoni M
    Mult Scler; 2024 Mar; ():13524585241228103. PubMed ID: 38456514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethical use of off-label disease-modifying therapies for multiple sclerosis.
    Laurson-Doube J; Rijke N; Helme A; Baneke P; Banwell B; Viswanathan S; Hemmer B; Yamout B
    Mult Scler; 2021 Aug; 27(9):1403-1410. PubMed ID: 34304636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis.
    Wu X; Wang L; Shen L; Tang K
    EBioMedicine; 2022 Jul; 81():104102. PubMed ID: 35759920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.